Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion type Assertion NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_head.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion description "[Bioassay studies indicate that these low levels of soluble CD95 in the CSF of some patients with malignant glioma cells are unlikely to interfere with CD95-based immunotherapy of malignant gliomas in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_provenance.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion evidence source_evidence_literature NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_provenance.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion SIO_000772 10066095 NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_provenance.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion wasDerivedFrom befree-20140225 NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_provenance.
- NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_assertion wasGeneratedBy ECO_0000203 NP800264.RAmvy6-NthtHoQqBqeZfm4kGI4HJjaELBQA_CRXje_gvU130_provenance.